Mutated CD200 Protein Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases often require high doses to achieve clinical efficacy, leading to increased costs and potential side effects, while also struggling to effectively modulate immune responses.
Innovation Solution
Development of mutated CD200 proteins with specific mutations at amino acid residues 130 and/or 131, which exhibit higher affinity binding to the CD200 receptor, and their use in fusion proteins or pharmaceutical compositions to treat autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type CD200 protein is used to treat autoimmune diseases, then the treatment can be administered, but the binding affinity to CD200 receptor is insufficient requiring high doses to achieve clinical efficacy
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations (K130F, I131F, K130Y, or combinations) at positions 130 and/or 131 of the CD200 protein sequence. These mutations alter the binding interface parameters to enhance affinity for the CD200 receptor, enabling effective treatment at lower doses compared to wild-type CD200
2Reliability
If high doses of CD200 protein are used to achieve clinical efficacy, then the immune modulation effect is sufficient, but the treatment cost increases and side effects increase
Solution Approach 1:
By changing the amino acid sequence parameters through specific mutations at positions 130 and/or 131, the patent enhances binding affinity which directly improves clinical efficacy at lower doses, thereby reducing side effects and treatment costs associated with high-dose therapies
3Duration of action of stationary object
If wild-type CD200 protein is used, then the protein structure is simple, but the residence time on CD200 receptor is insufficient reducing treatment effectiveness
Solution Approach 1:
The patent modifies the protein structure parameters through targeted amino acid mutations at positions 130 and/or 131. These changes enhance the interaction strength with the CD200 receptor, extending residence time without requiring complex structural modifications or fusion proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated CD200 proteins demonstrate enhanced binding affinity and residence time on the CD200 receptor, providing greater clinical efficacy at lower doses and potentially reducing treatment costs and side effects.
Implementation Method 1
mutated CD200 proteins which bind with greater affinity to the CD200 receptor than wild-type CD200
Data Source
AI summary
The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than wild-type CD200, in particular the invention relates to a mutated CD200 protein comprising specific mutations at amino acid residue position 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein portion directly or via an optional linker portion, a pharmaceutical composition comprising the protein as defined herein and uses thereof.